Research and Markets has announced the addition of the "Scar - Pipeline Review, H2 2016" report to their offering.
Scar pipeline therapeutics constitutes close to 24 molecules, out of which approximately 21 molecules are developed by Companies and the remaining by Universities/Institutes. Our latest report Scar - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Scars, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red-to-purple fibrous tissue that over time usually becomes flatter and lighter in color. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 15 and 1, respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in therapeutic development for Scars and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/bxd5bx/scar_pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006006383/en/Business Wire
Last updated on: 06/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.